131 related articles for article (PubMed ID: 29348105)
1. Report: Preparation of levodopa/carbidopa compound drug resins.
Liu H; Ding H; Zhang D; Fengsi -; Sun C
Pak J Pharm Sci; 2018 Jan; 31(1):205-211. PubMed ID: 29348105
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and optimization of preparative variables for controlled-release floating microspheres of levodopa/carbidopa.
Choudhary H; Agrawal AK; Malviya R; Yadav SK; Jaliwala YA; Patil UK
Pharmazie; 2010 Mar; 65(3):194-8. PubMed ID: 20383939
[TBL] [Abstract][Full Text] [Related]
3. The stability of carbidopa in solution.
Pappert EJ; Lipton JW; Goetz CG; Ling ZD; Stebbins GT; Carvey PM
Mov Disord; 1997 Jul; 12(4):608-10. PubMed ID: 9251084
[No Abstract] [Full Text] [Related]
4. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
[No Abstract] [Full Text] [Related]
5. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Silver DE
Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
[TBL] [Abstract][Full Text] [Related]
6. Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide.
Qu Y; Lai WL; Xin YR; Zhu FQ; Zhu Y; Wang L; Ding YP; Xu Y; Liu HF
AAPS PharmSciTech; 2019 Sep; 20(8):312. PubMed ID: 31529266
[TBL] [Abstract][Full Text] [Related]
7. Levodopa stability in solution: time course, environmental effects, and practical recommendations for clinical use.
Pappert EJ; Buhrfiend C; Lipton JW; Carvey PM; Stebbins GT; Goetz CG
Mov Disord; 1996 Jan; 11(1):24-6. PubMed ID: 8771063
[TBL] [Abstract][Full Text] [Related]
8. Stability of levodopa/carbidopa solutions.
Cedarbaum JM
Mov Disord; 1997 Jul; 12(4):625. PubMed ID: 9251095
[No Abstract] [Full Text] [Related]
9. Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach.
Bartos C; Pallagi E; Szabó-Révész P; Ambrus R; Katona G; Kiss T; Rahimi M; Csóka I
Eur J Pharm Sci; 2018 Oct; 123():475-483. PubMed ID: 30076956
[TBL] [Abstract][Full Text] [Related]
10. Carbidopa/levodopa extended-release capsules (Rytary).
Med Lett Drugs Ther; 2015 Apr; 57(1467):59-60. PubMed ID: 25897548
[No Abstract] [Full Text] [Related]
11. Clinical studies with and pharmacokinetic considerations of sustained-release levodopa.
LeWitt PA
Neurology; 1992 Jan; 42(1 Suppl 1):29-32; discussion 57-60. PubMed ID: 1549198
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical design and development of a Sinemet controlled-release formulation.
Dempski RE; Scholtz EC; Oberholtzer ER; Yeh KC
Neurology; 1989 Nov; 39(11 Suppl 2):20-4. PubMed ID: 2685648
[TBL] [Abstract][Full Text] [Related]
13. Unforeseen beneficial effects of controlled-release levodopa-carbidopa (Sinemet CR).
Makela EH; Cutlip WD
J Neuropsychiatry Clin Neurosci; 1992; 4(2):234-5. PubMed ID: 1627988
[No Abstract] [Full Text] [Related]
14. Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.
Othman AA; Rosebraugh M; Chatamra K; Locke C; Dutta S
J Parkinsons Dis; 2017; 7(2):275-278. PubMed ID: 28211816
[TBL] [Abstract][Full Text] [Related]
15. Continuous Transdermal Delivery of L-DOPA Based on a Self-Assembling Nanomicellar System.
Sintov AC; Levy HV; Greenberg I
Pharm Res; 2017 Jul; 34(7):1459-1468. PubMed ID: 28405912
[TBL] [Abstract][Full Text] [Related]
16. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.
Deleu D; Jacques M; Michotte Y; Ebinger G
Neurology; 1989 Nov; 39(11 Suppl 2):88-92; discussion 95. PubMed ID: 2685654
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Pahwa R; Koller WC
Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
[No Abstract] [Full Text] [Related]
18. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
Block G; Liss C; Reines S; Irr J; Nibbelink D
Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
[TBL] [Abstract][Full Text] [Related]
19. Controlled release levodopa-carbidopa (CR-5) in the management of parkinsonian motor fluctuations.
Juncos JL; Fabbrini G; Mouradian MM; Chase TN
Arch Neurol; 1987 Oct; 44(10):1010-2. PubMed ID: 3632371
[TBL] [Abstract][Full Text] [Related]
20. Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication.
Salomone G; Marano M; di Biase L; Melgari JM; Di Lazzaro V
Parkinsonism Relat Disord; 2015 Sep; 21(9):1124-5. PubMed ID: 26242552
[No Abstract] [Full Text] [Related]
[Next] [New Search]
